DOI record:
{
"DOI": "10.1155/2022/3014686",
"ISSN": [
"1687-8647",
"1687-8639"
],
"URL": "http://dx.doi.org/10.1155/2022/3014686",
"abstract": "<jats:p>Background. An in-silico screen identified mebendazole with potential antiviral activity that could be a repurposed drug against SARS-CoV-2. Mebendazole is a well-tolerated and cheap antihelminthic agent that is readily available worldwide and thus could be a therapeutic tool in the fight against COVID-19. Methods. This is an observational retrospective study of PCR-confirmed COVID-19 patients who received mebendazole with the intention-to-treat. The study included an inpatient cohort (157 inpatients) and an outpatient cohort (185 outpatients). Of the 157 inpatients and 185 outpatients, 68 (43.3%) and 94 (50.8%) received mebendazole, respectively. Patients who presented within the same timeframe but did not receive mebendazole were used as controls. Patients received standard-of-care treatment including remdesivir, dexamethasone, and anticoagulants as deemed necessary by the treating physician. The following clinical outcomes were evaluated: for the inpatient cohort, length of stay (LOS) at the hospital, need for ventilation (combined invasive and noninvasive), and mortality; for the outpatient cohort, time to symptom resolution, need for hospitalization, and mortality. Results. For the inpatient cohort, the median age did not differ between the treatment and control groups; 62 (56, 67) vs. 62 (56, 68), <jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\">\n <mi>P</mi>\n </math>\n </jats:inline-formula>, and there was a comparable proportion of males in both groups; 43 (63%) vs. 55 (62%), <jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\">\n <mi>P</mi>\n <mo>=</mo>\n <mn>0.85</mn>\n </math>\n </jats:inline-formula>. The hospital LOS was 3.5 days shorter in the treatment group compared to the control group (<jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\">\n <mi>P</mi>\n <mo><</mo>\n <mn>0.001</mn>\n </math>\n </jats:inline-formula>). There were fewer patients who required invasive or noninvasive ventilation in the treatment group, 2 (2.9%) vs. 7 (7.9%), and the mortality rate is lower in the treatment group, 3 (4.4%) vs. 8 (9.0%), though the differences did not reach statistical significance. For the outpatient cohort, the median age was lower in the treatment group compared with the control group; 40 (34, 48) vs. 48 (41, 54), <jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\">\n <mi>P</mi>\n <mo><</mo>\n <mn>0.001</mn>\n </math>\n </jats:inline-formula>. There was a comparable proportion of males between both groups; 50 (53%) vs. 52 (57%), <jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M5\">\n <mi>P</mi>\n <mo>=</mo>\n <mn>0.59</mn>\n </math>\n </jats:inline-formula>. Patients in the treatment group were 3.3 days closer to symptom resolution (<jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M6\">\n <mi>P</mi>\n <mo><</mo>\n <mn>0.001</mn>\n </math>\n </jats:inline-formula>). There were numerically fewer patients requiring hospitalization in the treatment group compared with the control group, 3 (3.2%) vs. 6 (6.6%), though this did not reach statistical significance (<jats:inline-formula>\n <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M7\">\n <mi>P</mi>\n <mo>=</mo>\n <mn>0.33</mn>\n </math>\n </jats:inline-formula>). Conclusion. In this retrospective observational study, the use of mebendazole in COVID-19 patients was associated with shorter hospitalizations in the inpatient cohort and shorter durations of symptom resolution in the outpatient cohort. The findings from this small observational study are hypothesis-generating and preclude drawing conclusions about clinical efficacy. Further studies are needed to examine the role of mebendazole in the treatment of COVID-19 patients.</jats:p>",
"alternative-id": [
"3014686",
"3014686"
],
"author": [
{
"affiliation": [
{
"name": "School of Medicine, Aim Shams University, Cairo, Egypt"
}
],
"family": "Galal",
"given": "Mostafa W.",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Department of Internal Medicine Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
}
],
"family": "Ahmed",
"given": "Mahmoud",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Statistical Science, Southern Methodist University, Dallas, TX 75275, USA"
},
{
"name": "Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
}
],
"family": "Shao",
"given": "Yanqiu",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
},
{
"name": "McDermott Center for Human Growth and Development and Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
}
],
"family": "Xing",
"given": "Chao",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Egyptian Center for Research in Regenerative Medicine, Cairo, Egypt"
}
],
"family": "Ali",
"given": "Wael",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Clinical Pathology, Cura El-Nasr Hospitals, Cairo, Egypt"
}
],
"family": "Baly",
"given": "Abd Elhamid",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Radiology, Cura El-Nasr Hospitals, Helwan university, Cairo, Egypt"
}
],
"family": "Elfiky",
"given": "Abdallah",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
}
],
"family": "Amer",
"given": "Khaled",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Epartments Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
}
],
"family": "Schoggins",
"given": "John",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-4745-366X",
"affiliation": [
{
"name": "Departments Biophysics and Molecular Biology and Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
},
{
"name": "Department of Internal Medicine Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"
}
],
"authenticated-orcid": true,
"family": "Sadek",
"given": "Hesham A.",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-8921-259X",
"affiliation": [
{
"name": "Department of Clinical Pathology, Cura El-Nasr Hospitals, Cairo, Egypt"
}
],
"authenticated-orcid": true,
"family": "Gobara",
"given": "Zeinab N.",
"sequence": "additional"
}
],
"container-title": "Advances in Virology",
"container-title-short": "Advances in Virology",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
12,
10
]
],
"date-time": "2022-12-10T19:35:09Z",
"timestamp": 1670700909000
},
"deposited": {
"date-parts": [
[
2022,
12,
10
]
],
"date-time": "2022-12-10T19:35:12Z",
"timestamp": 1670700912000
},
"editor": [
{
"affiliation": [],
"family": "Lin",
"given": "Shih-Chao",
"sequence": "additional"
}
],
"indexed": {
"date-parts": [
[
2022,
12,
11
]
],
"date-time": "2022-12-11T05:27:10Z",
"timestamp": 1670736430808
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2022,
12,
10
]
]
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
12,
10
]
],
"date-time": "2022-12-10T00:00:00Z",
"timestamp": 1670630400000
}
}
],
"link": [
{
"URL": "http://downloads.hindawi.com/journals/av/2022/3014686.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://downloads.hindawi.com/journals/av/2022/3014686.xml",
"content-type": "application/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "http://downloads.hindawi.com/journals/av/2022/3014686.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "98",
"original-title": [],
"page": "1-6",
"prefix": "10.1155",
"published": {
"date-parts": [
[
2022,
12,
10
]
]
},
"published-print": {
"date-parts": [
[
2022,
12,
10
]
]
},
"publisher": "Hindawi Limited",
"reference": [
{
"DOI": "10.1080/01652176.2020.1727993",
"doi-asserted-by": "publisher",
"key": "1"
},
{
"DOI": "10.1038/s41586-020-2008-3",
"doi-asserted-by": "publisher",
"key": "2"
},
{
"DOI": "10.1038/s41586-020-2012-7",
"doi-asserted-by": "publisher",
"key": "3"
},
{
"DOI": "10.1038/s41467-021-22580-8",
"doi-asserted-by": "publisher",
"key": "4"
},
{
"DOI": "10.1038/s41564-020-00835-2",
"doi-asserted-by": "publisher",
"key": "5"
},
{
"DOI": "10.1101/2021.06.17.21258639",
"doi-asserted-by": "publisher",
"key": "6"
},
{
"DOI": "10.1126/science.abl4784",
"doi-asserted-by": "publisher",
"key": "7"
},
{
"DOI": "10.1136/bmj.n2713",
"doi-asserted-by": "publisher",
"key": "8"
},
{
"article-title": "Identification of atovaquone as and mebendazole as repurposed drugs with antiviral activity against SARS-CoV-2 chemRxiv",
"author": "A. F. Mahmoud Ahmed",
"key": "9",
"year": "2021"
},
{
"DOI": "10.1001/jama.1974.03240100030022",
"doi-asserted-by": "publisher",
"key": "10"
},
{
"DOI": "10.1128/CMR.14.1.114-128.2001",
"doi-asserted-by": "publisher",
"key": "11"
},
{
"DOI": "10.1136/bmj.l4257",
"doi-asserted-by": "publisher",
"key": "12"
},
{
"DOI": "10.3347/kjp.2021.59.3.189",
"doi-asserted-by": "publisher",
"key": "13"
},
{
"DOI": "10.1016/0020-7519(88)90175-0",
"doi-asserted-by": "publisher",
"key": "14"
},
{
"DOI": "10.3390/cancers11091284",
"doi-asserted-by": "publisher",
"key": "15"
},
{
"article-title": "Management protocol for COVID-19 patients version 1.4/30th may 2020 ministry of health and population (MOHP), Egypt",
"author": "H. H. Masoud",
"key": "16",
"year": "2020"
},
{
"DOI": "10.1186/s12879-018-3201-y",
"doi-asserted-by": "publisher",
"key": "17"
},
{
"author": "LiverTox",
"key": "18",
"volume-title": "Clinical and Research Information on Drug-Induced Liver Injury",
"year": "2012"
},
{
"DOI": "10.1080/00034983.1982.11687523",
"doi-asserted-by": "publisher",
"key": "19"
},
{
"DOI": "10.1186/s13643-021-01636-2",
"doi-asserted-by": "publisher",
"key": "20"
},
{
"DOI": "10.1371/journal.pone.0252411",
"doi-asserted-by": "publisher",
"key": "21"
},
{
"DOI": "10.1007/s40620-020-00790-5",
"doi-asserted-by": "publisher",
"key": "22"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"doi-asserted-by": "publisher",
"key": "23"
},
{
"DOI": "10.1038/s41421-020-0156-0",
"doi-asserted-by": "publisher",
"key": "24"
},
{
"article-title": "Toxicology rounds: ivermectin not the crisis it’s claimed to Be",
"author": "L. Gussow",
"journal-title": "Emergency Medicine News",
"key": "25",
"volume": "43",
"year": "2021"
},
{
"article-title": "Identification of atovaquone and mebendazole as repurposed drugs with antiviral activity against SARS-CoV-2 (version 5)",
"author": "M. Ahmed",
"key": "26",
"year": "2021"
}
],
"reference-count": 26,
"references-count": 26,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.hindawi.com/journals/av/2022/3014686/"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases",
"Virology"
],
"subtitle": [],
"title": "The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study",
"type": "journal-article",
"volume": "2022"
}
